Emerging Drug Target In Pancreatic Cancer: Placing Sirtuin 1 on the Canvas

Author(s): Marc Giry-Laterriere, Andreia V. Pinho, Nils Eling, Lorraine Chantrill, Ilse Rooman

Journal Name: Current Cancer Drug Targets

Volume 15 , Issue 6 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Sirtuin 1 is a protein deacetylase that regulates a large number of proteins often functionally implicated in tumor development and progression. Its pleiotropic function has turned SIRT1 into an attractive chemotherapeutic target, underscored by very promising preclinical results with SIRT1 inhibitors in the treatment of chronic myeloid leukemia. Here, we revisit the studies on SIRT1 as an emerging target for therapy in pancreatic cancer, a tumor with dismal outcomes for which currently few therapeutic options are available. We highlight those potential SIRT1 target genes that are commonly affected in pancreatic cancer according to recent genomic analyses.

Keywords: Chemotherapy, Deleted in breast cancer 1, genomic, mutation, pancreas, personalized medicine, Sirtuin 1.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [463 - 468]
Pages: 6
DOI: 10.2174/1568009615666150512102957
Price: $65

Article Metrics

PDF: 33